Moderna: COVID-19 vaccine about 93% effective through 6 months, booster shot will be needed before winter

COVID-19 Vaccine

FILE – In this file photo dated Wednesday, Feb. 17, 2021, three vials of the Moderna COVID-19 Vaccine are pictured in a new coronavirus vaccination center at the ‘Velodrom’ (velodrome-stadium) in Berlin, Germany. The European Medicines Agency has recommended approving Moderna’s COVID-19 vaccine for children aged 12 to 17, the first time the shot has been authorized for people under 18. In a decision on Friday, July 23, 2021 the EU drug regulator said research in more than 3,700 children aged 12 to 17 showed that the Moderna vaccine — already given the OK for adults across Europe — produced a comparable antibody response. (AP Photo/Michael Sohn, File)

TAMPA, Fla. (WFLA) — Drugmaker Moderna says it has seen its COVID-19 vaccine’s antibody levels decline over time and believes people who received two doses of it will need a booster shot before winter to protect against virus variants.

“We believe that increased force of infection resulting from Delta, non-pharmaceutical intervention (NPI) fatigue, and seasonal effects (moving indoors) will lead to an increase of breakthrough infections in vaccinated individuals,” the company said in its second-quarter earnings presentation Thursday.

According to the presentation, Moderna’s COVID-19 shot was about 93% effective through six months after the second dose, but antibody levels were expected to wane and impact vaccine efficacy.

“Given this intersection, we believe dose 3 booster will likely be necessary prior to the winter season,” the presentation said.

The COVID-19 vaccine is Moderna’s only commercially approved product. It also is developing several vaccines that aim to guard against the flu, Zika and HIV among other viruses. Those are all in early stages of clinical testing, according to its website.

The company also is testing a potential booster shot for the COVID-19 vaccine.

Moderna’s COVID-19 vaccine brought in more than $4 billion in second-quarter sales, helping to push the vaccine developer into a profit.

Moderna’s announcement comes after pharmaceutical giant Pfizer Inc. said its COVID-19 vaccine remained effective months after the second dose and had become a top seller. It brought in nearly half the company’s revenue — $7.84 billion from direct sales and revenue split with its partner, Germany’s BioNTech.

Moderna’s COVID-19 vaccine has received emergency authorization for use in more than 50 countries.

The Associated Press contributed to this report.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

 

Senatara COVID-19 Infographic (Dec. 2020)

Trending Stories

WAVY Twitter Widget

***Don’t Miss Module Removal CSS***

WAVY Facebook